Related trials
Buse, 2011 - exenatide vs placebo add on insulin
Lewin, 2010 - linagliptin vs placebo (add on to sulphonylurea)
DURATION-2 (Bergenstal) (vs sitagliptin), 2010 - exenatide vs sitagliptin
DURATION-3 (Diamant), 2010 - exenatide vs insulin glargine
Ratner DRI6012, 2010 - lixisenatide vs placebo add on MET
DURATION-2 (Bergenstal) (vs pioglitazone), 2010 - exenatide vs pioglitazone
Goodman, 2009 - vildagliptin vs placebo (add on to metformin)
HOME, 2009 - metformin vs placebo
LEAD-2 (Nauck) (vs placebo), 2009 - liraglutide vs placebo add on MET
Nauck (Sulf vs pbo), 2009 - vs placebo
9607, 2009 - exenatide vs placebo add on MET+/-SU
Li, 2009 - nateglinide vs repaglinide
LEAD-2 (vs MET), 2009 - liraglutide vs metformin
Ferrannini, 2009 - vildagliptin vs Sulfonylurea (add on to metformin)
LEAD-3 mono (Garber), 2009 - liraglutide vs glimepiride
Kaku, 2009 - mitiglinide vs placebo (on top pioglitazone )
COSMIC, 2009 - vs
LEAD-2 (Nauck) (vs glimepiride), 2009 - liraglutide vs glimepiride add on MET
DeFronzo, 2009 - saxagliptin vs placebo (add on to metformin)
RECORD, 2009 - rosiglitazone vs standard glucose-lowering drugs
Nauck, 2009 - alogliptin vs placebo (add on to metformin)
Nauck (vs GLP-1 analog), 2009 - vs GLP-1 analog
Filozof, 2009 - vildagliptin as add-on therapy vs gliclazide
Bolli, 2008 - vildagliptin vs pioglitazone (on top of metformin)
Moretto, 2008 - exenatide vs placebo
See also:
All test diabète clinical trials
All diabetes clinical trials
All type 2 diabetes - sanofi clinical trials
All clinical trials of insulin secretagogues peptides (incretins)
All clinical trials of liraglutide
|
|
Treatments
Studied treatment |
Liraglutide 0.045–0.75 mg daily
|
Control treatment |
Metformin
|
Concomittant treatment |
None |
Patients
Patients |
subjects with Type 2 diabetes |
Baseline characteristics |
Age (year) |
53 |
Duration of diabetes (year) |
4.7 y |
HbA1c (%) |
7.0 |
BMI |
34.5 |
Add-on to |
None |
|
Method and design
Randomized effectives |
176 / 34 (studied vs. control) |
Blinding |
double blind (not adequate) |
Follow-up duration |
12 weeks |
Remarks |
dose response study |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
severe hypoglycemia
0 / 176
0 / 34
classic
0,19 [0,00;48,78]
vomiting
4 / 176
1 / 34
classic
0,77 [0,09;6,70]
all hypoglycemia
5 / 176
2 / 34
classic
0,48 [0,10;2,39]
nausea
7 / 176
2 / 34
classic
0,68 [0,15;3,12]
All cause death
0 / 176
0 / 34
classic
0,19 [0,00;48,78]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
severe hypoglycemia
|
0 / 176 (0,3%) |
0 / 34 (1,5%) |
0,19 |
[0,00;9,57] |
|
12053 |
vomiting
|
4 / 176 (2,3%) |
1 / 34 (2,9%) |
0,77 |
[0,09;6,70] |
|
12053 |
all hypoglycemia
|
5 / 176 (2,8%) |
2 / 34 (5,9%) |
0,48 |
[0,10;2,39] |
|
12053 |
nausea
|
7 / 176 (4,0%) |
2 / 34 (5,9%) |
0,68 |
[0,15;3,12] |
|
0 |
All cause death
|
0 / 176 (0,3%) |
0 / 34 (1,5%) |
0,19 |
[0,00;9,57] |
|
12053 |
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
12053: Monami M, Marchionni N, Mannucci EGlucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.Eur J Endocrinol 2009;160:909-17
0:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
vomiting |
2,27% |
2,94% |
-6,7‰
|
all hypoglycemia |
2,84% |
5,88% |
-30,4‰
|
nausea |
3,98% |
5,88% |
-19,1‰
|
Meta-analysis of all similar trials:
antidiabetic drugs in test diabète for type 2 daibetes (NIDD)
insulin secretagogues peptides (incretins) in diabetes for all type of patients
insulin secretagogues peptides (incretins) in type 2 diabetes - sanofi for all type of patients
Reference(s)
-
Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O.
Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes..
Diabet Med 2005;22:1016-23
- 10.1111/j.1464-5491.2005.01567.x
Pubmed
|
Hubmed
| Fulltext
|